BACKGROUND: Protective effect of pretreatment with ghrelin against different forms of acute pancreatitis (AP) has been recently reported. Moreover, the healing properties of this peptide have been proved in AP evoked by cerulein. However, no studies have investigated whether the administration of ghrelin affects the course of ischemia/reperfusion-induced AP. AIM: The aim of this study was to evaluate the impact of ghrelin therapy on the course of necrotizing inflammation of the pancreas and to test its impact on peroxidation of lipids and antioxidant defense system in the acutely inflamed pancreas. METHODS: Acute inflammation of the pancreas was triggered by pancreatic ischemia which was then followed by reperfusion of the gland. Ghrelin (8 nmol/kg/dose) was administered to intraperitoneally twice daily, 24h after the initiation of AP. The impact of ghrelin on the course of necrotizing pancreatitis was evaluated between 1 and 21 days, and involved histological, functional, and biochemical analyses. RESULTS: Treatment with ghrelin ameliorated morphological signs of pancreatic damage including edema, acinar cells vacuolization, hemorrhages, acinar necrosis, leukocytic infiltration of the gland, and led to its earlier regeneration. These effects were accompanied by an improvement in pancreatic blood flow, enhanced DNA synthesis, reduced serum level of pro- inflammatory interleukin-1β, decreased levels of malondialdehyde and an enhanced superoxide dismutase activity in pancreatic tissue. CONCLUSIONS: Ghrelin exerts a pronounced therapeutic effect against ischemia-reperfusion-induced pancreatitis. The mechanisms involved are likely multifactorial and are mediated by its anti-inflammatory, as well as anti-oxidative properties.
BACKGROUND: Protective effect of pretreatment with ghrelin against different forms of acute pancreatitis (AP) has been recently reported. Moreover, the healing properties of this peptide have been proved in AP evoked by cerulein. However, no studies have investigated whether the administration of ghrelin affects the course of ischemia/reperfusion-induced AP. AIM: The aim of this study was to evaluate the impact of ghrelin therapy on the course of necrotizing inflammation of the pancreas and to test its impact on peroxidation of lipids and antioxidant defense system in the acutely inflamed pancreas. METHODS: Acute inflammation of the pancreas was triggered by pancreatic ischemia which was then followed by reperfusion of the gland. Ghrelin (8 nmol/kg/dose) was administered to intraperitoneally twice daily, 24h after the initiation of AP. The impact of ghrelin on the course of necrotizing pancreatitis was evaluated between 1 and 21 days, and involved histological, functional, and biochemical analyses. RESULTS: Treatment with ghrelin ameliorated morphological signs of pancreatic damage including edema, acinar cells vacuolization, hemorrhages, acinar necrosis, leukocytic infiltration of the gland, and led to its earlier regeneration. These effects were accompanied by an improvement in pancreatic blood flow, enhanced DNA synthesis, reduced serum level of pro- inflammatory interleukin-1β, decreased levels of malondialdehyde and an enhanced superoxide dismutase activity in pancreatic tissue. CONCLUSIONS:Ghrelin exerts a pronounced therapeutic effect against ischemia-reperfusion-induced pancreatitis. The mechanisms involved are likely multifactorial and are mediated by its anti-inflammatory, as well as anti-oxidative properties.
Authors: Aleksandra Matuszyk; Dagmara Ceranowicz; Zygmunt Warzecha; Piotr Ceranowicz; Krzysztof Fyderek; Krystyna Gałązka; Jakub Cieszkowski; Joanna Bonior; Jolanta Jaworek; Małgorzata Pihut; Artur Dembiński Journal: Biomed Res Int Date: 2015-12-02 Impact factor: 3.411
Authors: Aleksandra Matuszyk; Piotr Ceranowicz; Zygmunt Warzecha; Jakub Cieszkowski; Dagmara Ceranowicz; Krystyna Gałązka; Joanna Bonior; Jolanta Jaworek; Krzysztof Bartuś; Krzysztof Gil; Rafał Olszanecki; Artur Dembiński Journal: Int J Mol Sci Date: 2016-09-01 Impact factor: 5.923
Authors: Joanna Bonior; Piotr Ceranowicz; Ryszard Gajdosz; Beata Kuśnierz-Cabala; Piotr Pierzchalski; Zygmunt Warzecha; Artur Dembiński; Michał Pędziwiatr; Michalina Kot; Anna Leja-Szpak; Katarzyna Nawrot-Porąbka; Paweł Link-Lenczowski; Rafał Olszanecki; Krzysztof Bartuś; Jolanta Jaworek Journal: Int J Mol Sci Date: 2017-05-02 Impact factor: 5.923
Authors: Joanna Bonior; Zygmunt Warzecha; Piotr Ceranowicz; Ryszard Gajdosz; Piotr Pierzchalski; Michalina Kot; Anna Leja-Szpak; Katarzyna Nawrot-Porąbka; Paweł Link-Lenczowski; Michał Pędziwiatr; Rafał Olszanecki; Krzysztof Bartuś; Rafał Trąbka; Beata Kuśnierz-Cabala; Artur Dembiński; Jolanta Jaworek Journal: Int J Mol Sci Date: 2017-06-30 Impact factor: 5.923
Authors: Jakub Bukowczan; Zygmunt Warzecha; Piotr Ceranowicz; Beata Kuśnierz-Cabala; Romana Tomaszewska Journal: PLoS One Date: 2015-07-30 Impact factor: 3.240
Authors: Aleksandra Matuszyk; Piotr Ceranowicz; Zygmunt Warzecha; Jakub Cieszkowski; Joanna Bonior; Jolanta Jaworek; Beata Kuśnierz-Cabala; Peter Konturek; Tadeusz Ambroży; Artur Dembiński Journal: Oxid Med Cell Longev Date: 2015-12-20 Impact factor: 6.543
Authors: Zygmunt Warzecha; Paweł Sendur; Piotr Ceranowicz; Jakub Cieszkowski; Marcin Dembiński; Ryszard Sendur; Joanna Bonior; Jolanta Jaworek; Tadeusz Ambroży; Rafał Olszanecki; Beata Kuśnierz-Cabala; Kaczmarzyk Tomasz; Romana Tomaszewska; Artur Dembiński Journal: Int J Mol Sci Date: 2017-04-21 Impact factor: 5.923